GC
PTGX icon

Globeflex Capital’s Protagonist Therapeutics PTGX Stock Holding History

Globeflex Capital’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,627
Closed -$118K – 489
2024
Q3 		$118K Buy
+2,627
New +$106K 0.01% 366

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Globeflex Capital's PTGX Position: Q4 2024 in Review

Globeflex Capital sold out of Protagonist Therapeutics (PTGX) in Q4 2024, closing a stake of 2,627 shares — an estimated $118K sold.

Globeflex Capital first reported a position in PTGX in Q3 2024 and held it in 1 quarter. The position peaked at $118K in Q3 2024. 241 funds tracked by Wall St. Rank hold PTGX as of Q4 2024.

  • Globeflex Capital reported no remaining Protagonist Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Globeflex Capital sold 2,627 Protagonist Therapeutics shares in Q4 2024, an estimated $118K.
  • Globeflex Capital first reported a position in Protagonist Therapeutics in Q3 2024 and held it in 1 quarter.
  • Globeflex Capital's Protagonist Therapeutics position peaked at $118K in Q3 2024.
  • 241 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2024.

Based on Globeflex Capital's 13F filing for Q4 2024, filed 10 Feb 2025.